(Q33848509)

29 July 2017

1 reference

title

The management of high-risk lymphoblastic leukaemia in children (English)

1 reference

29 July 2017

1 reference

Chessells JM

1

1 reference

PubMed ID

10691845

29 July 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

British Journal of Haematology

29 July 2017

1 reference

29 July 2017

108

1 reference

29 July 2017

204-216

1 reference

29 July 2017

2

1 reference

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

29 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia in first remission: a cooperative study of the Groupe d'Etude de la Greffe de Moelle Osseuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Ital

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Critical study of prognostic factors in childhood acute lymphoblastic leukaemia: differences in outcome are poorly explained by the most significant prognostic variables. Fralle group. French Acute Lymphoblastic Leukaemia study group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non-high-risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996. Nordic Society of Paediatric Haematology and Oncol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Acute leukaemia 1959-64: factors affecting prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Hematologic malignancies with t(4;11)(q21;q23)--a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Molecular cytogenetics of childhood hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Second neoplasms after acute lymphoblastic leukemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2000.01849.X

10.1046/J.1365-2141.2000.01849.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10691845